OBR – News, Perspective, Catalyst

Today's Oncology News

Opt In Search Archives

AstraZeneca's Imfinzi Combination Fails Advanced Lung C...

(Reuters) Aug 21, 2019 - A combination of AstraZeneca’s lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of...

BRCA1/2 Genetic Testing Recommendations Still Leave Iss...

(Penn Medicine) Aug 20, 2019 - Leaders in BRCA research say screening recommendations from the US Preventive Services Task Force are a positiv...

Why A Promising, Potent Cancer Therapy Isn't Used In th...

(WIRED) Aug 21, 2019 - Globally, carbon ion therapy is viewed as the next horizon of cancer care. Yet the therapy has followed an odd traject...

Featured Content

Marwan G. Fakih, MD, on combining regorafenib + checkpoint inhibition in advanced CRC

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Edward Garon, MD, Associate Professor of Medicine, Geffen School of Medicine at UCLA, discuss lung cancer highlights from ASCO 2019.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discuss HCC highlights from ASCO 2019.

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Scott Kopetz, MD, PhD, FACP, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson, provide CRC clinical update post World GI '19.

At ASCO, a symposium delved into the ever-expanding importance of real-world data. Several presentations covered the use of RWD to broaden trial eligibility or identify outcomes. There are still hurdles, i.e., improving data collection and interoperability, but good progress is being made.

Oncologists may have more control than we actually think in terms of keeping drug costs down without compromising quality of care. We report on studies from ASCO '19 that look at innovative ways for physicians to get involved. Take a look at what happened at ASCO’s Town Hall on Drug Pricing too.

Podcasts

Colorectal Cancer (CRC) - Scott Kopetz, MD, and Robert Figlin, MD, provide post World GI '19 clinical update

00:00

Listen on
Apple Podcasts

Listen on
Google Play

Listen on
Spotify

Title

Released

Hepatocellular carcinoma (HCC) - Daneng Li, MD and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

07/02/19

Breast Cancer – Neelima Denduluri, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

06/21/19

Pancreatic Cancer – Vincent Chung, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

06/21/19

Lung Cancer - Edward Garon, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

06/21/19

Expert Video Insights

Search by

Sandip Patel, MD, on treating non-squamous NSCLC patients expressing high levels of PD-L1

Tomasz M. Beer MD, FACP, discusses outcomes from the TITAN study in mCSPC

OBR Green

View Archives

July 2019 Edition

Oncologists may have more control than we actually think in terms of keeping drug costs down without compromising quality of care. We report on studies from ASCO '19 that look at innovati...

July 2019 Edition

At ASCO, a symposium delved into the ever-expanding importance of real-world data. Several presentations covered the use of RWD to broaden trial eligibility or identify outcomes. There ar...

Blog

Rapid Integration of Information Presented at 2019 ASCO...

Jul 15, 2019

Introduction OBR and MDoutlook are pleased to share excerpts from the most recent MDoutlook OncoPolls™ following this year’s ASCO annual meeting in ...

Targeting Driver Mutations in mNSCLC: Impact of 2019 A...

Jul 11, 2019

Introduction OBR and MDoutlook are pleased to share more excerpts from the most recent MDoutlook OncoPolls™ following this year’s ASCO annual meetin...

nmCRPC and mHSPC: Immediate Impact of 2019 ASCO Annual...

Jul 08, 2019

Introduction OBR and MD Outlook are pleased to share excerpts from the most recent MDoutlook’s OncoPolls™ from his year’s ASCO annual meeting in Chi...

OBR Tools

Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.

Learn More

The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.

Learn More

Oncology Events Calendar

May 29, 2020

1

Friday

(1)

August 22, 2019

Highlights from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting: Caring for Every Patient, Learning from Every Patient Part I of Your Guide to the Latest Cancer Research and Treatment (CancerCare Connect® Education Workshop)

[by phone or online via webcast]

August 24 - 26, 2019

20th Asia-Pacific Prostate Cancer Conference 2019

Melbourne, Australia

August 27, 2019

Highlights from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting: Caring for Every Patient, Learning from Every Patient Part II of Your Guide to the Latest Cancer Research and Treatment (CancerCare Connect® Education Workshop)

[by phone or online via webcast]

September 5, 2019

NCCN Policy Summit: Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care

Washington, DC

September 12 - 14, 2019

12th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

San Francisco, CA

September 20 - 22, 2019

OBR Radar

Top 5 Market Moving Events

Date	Company and Product
Sep 02	Roche , Tecentriq® (atezolizumab) + Abraxane® + carboplatin Roche announced on Jan. 17, 2019 that the FDA had accepted the company’s sBLA for Tecentriq in combination with chemotherapy (Abraxane) and (carboplatin) for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations. The FDA is expected to make an approval decision by September 2, 2019. The sBLA is based on results from the phase 3 IMpower130 study, which met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS).
Sep 26	Genmab A/S / Janssen Biotech , Darzalex® (daratumumab) The FDA granted Priority Review for daratumumab in combination with bortezomib, thalidomide and dexamethasone as a treatment for newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant, Genmab A/S said on May 30, 2019. The PDUFA target action date is September 26, 2019. Genmab announced topline results from the phase 3 CASSIOPEIA trial of 1,085 newly diagnosed patients with previously untreated symptomatic multiple myeloma who are eligible for high dose chemotherapy and stem cell transplant in October 2018.
Oct 24	GlaxoSmithKline plc / Tesaro, Zejula® (niraparib) GSK announced on June 24, 2019 Tesaro, its oncology-focused business unit, submitted a supplemental New Drug Application (sNDA) to the FDA for Zejula. The sNDA supports a potential new indication for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with either 1) BRCA mutation or 2) homologous recombination deficiency (HRD) and has progressed more than six months after the last platinum-based chemotherapy. The niraparib sNDA is supported by data from the phase 2 QUADRA trial. The application has priority review with an action date of Oct. 24, 2019.
Oct 29	Bayer / Orion Corp. , darolutamide Bayer said on Apr. 29, 2019 that the FDA had accepted its new drug application (NDA) for darolutamide as a potential treatment for non-metastatic castration resistant prostate cancer (nmCRPC) and granted the NDA a Priority Review. The NDA and Priority Review status were based on data from the phase 3 ARAMIS trial which demonstrated a 59% reduction in the risk of metastases or death with darolutamide compared to placebo in men with nmCRPC. If the FDA greenlights it, darolutamide would be the third androgen receptor inhibitor approved for the indication in the U.S. Darolutamide is being co-developed by Bayer and Orion Corporation. It is not yet approved by any global health authority. Given the FDA's priority review of the investigational therapy, an approval decision should be due by Oct. 29, 2019.
Dec 31	Novartis, PDR001 + dabrafenib + trametinib The company reported on July 18, 2018, that results will be due in the 2nd half of 2019 from their phase 3 trial evaluating PD-1 inhibitor PDR001 + dabrafenib + trametinib vs placebo + dabrafenib + trametinib in treatment-naïve patients with metastatic or unresectable BRAFV600 mutant melanoma.